-The Guardian Don't believe the hype: GM is in the grip of a few firms that profit from selling the chemicals they engineer their seeds to resist Thirty years ago, genetic engineers hoped new technology would revolutionise world farming and reduce or even eliminate the need for fertilisers and pesticides. It was a noble idea that deserved success. But only promises came. In the 1990s the public was told genetic modification would...

-The Guardian Inequity such as that symbolised by Antilla, the world's richest home, thwarts poverty reduction – and policymakers must act If you want a glimpse across the yawning chasm that separates the world's super rich from the ultra poor, there's no better place than Mumbai's Altamount Road. Look up and you'll see Antilla, the world's most expensive home. With spectacular ocean views, swimming and gym facilities, and no fewer than three helipads,...

-The Hindu One of the most prominent features of India’s middle-class-driven public culture has been an obsession about our GDP growth rate, and a facile equation of that number with a sense of national achievement or impending arrival into affluence. In media headlines, political speeches, and everyday conversations, the GDP growth rate number — whether it is five per cent or eight per cent or whatever — has become a staple...

-The Guardian The media spotlight is on the role of smallholder farmers in poverty reduction and food security, but what they need is action on land rights and support to stand up to powerful partners With the launch of the Enough food for everyone If campaign, global food security is once again high on the public agenda. The UK campaign hopes to harness public support leading up to the meeting of the...

-The Economic Times Pharmaceutical multinationals have begun using the Right to Information law to launch pre-emptive legal action against local generic players to protect the market of patented drugs and delay the entry of low cost generic medicines in the 60,000-crore domestic drug market. MNCs are using such information to sue generic firms even at a stage when their marketing approval is still pending or during the few months' window between the...